198 results on '"Servicio Cántabro de Salud"'
Search Results
2. Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Inception Cohort (PRECISESADSI)
- Author
-
UCB Biopharma S.P.R.L., Atrys Health, National Research Council, Spain, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Servicio Cántabro de Salud, August Pi Sunyer Biomedical Research Institute, Karolinska Institutet, KU Leuven, Klinikum der Universität Köln, Hannover Medical School, Medical University of Vienna, Quartz Bio S.A., Andaluz Health Service, The Cyprus Foundation for Muscular Dystrophy Research, Universidad de Granada, University of Milan, Université Catholique de Louvain, University Hospital, Brest, University of Geneva, Switzerland, Szeged University, Bayer, Institut de Recherches Internationales Servier, Sanofi, Eli Lilly and Company, Charite University, Berlin, Germany, Centro Hospitalar do Porto, Institut d'Investigació Biomèdica de Bellvitge, and Innovative Medicines Initiative
- Published
- 2021
3. Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease Based on Artificial Intelligence. (NASHAI)
- Author
-
Servicio Cántabro de Salud
- Published
- 2019
4. Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases (PRECISESADS)
- Author
-
UCB Biopharma S.P.R.L., Atrys Health, National Research Council, Spain, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Servicio Cántabro de Salud, August Pi Sunyer Biomedical Research Institute, Karolinska Institutet, KU Leuven, Klinikum der Universität Köln, Hannover Medical School, Medical University of Vienna, Quartz Bio S.A., Andaluz Health Service, The Cyprus Foundation for Muscular Dystrophy Research, Universidad de Granada, University of Milan, Université Catholique de Louvain, University Hospital, Brest, University of Geneva, Switzerland, Szeged University, Bayer, Institut de Recherches Internationales Servier, Sanofi, Eli Lilly and Company, Charite University, Berlin, Germany, Centro Hospitalar do Porto, Institut d'Investigació Biomèdica de Bellvitge, and Innovative Medicines Initiative
- Published
- 2018
5. Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Case-control (PRECISESADST)
- Author
-
UCB Biopharma S.P.R.L., Atrys Health, National Research Council, Spain, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Servicio Cántabro de Salud, August Pi Sunyer Biomedical Research Institute, Karolinska Institutet, KU Leuven, Klinikum der Universität Köln, Hannover Medical School, Medical University of Vienna, Quartz Bio S.A., Andaluz Health Service, The Cyprus Foundation for Muscular Dystrophy Research, Universidad de Granada, University of Milan, Université Catholique de Louvain, University Hospital, Brest, University of Geneva, Switzerland, Szeged University, Bayer, Institut de Recherches Internationales Servier, Sanofi, Eli Lilly and Company, Charite University, Berlin, Germany, Centro Hospitalar do Porto, Institut d'Investigació Biomèdica de Bellvitge, and Innovative Medicines Initiative
- Published
- 2018
6. HLA association with the susceptibility to anti-synthetase syndrome.
- Author
-
Foundation for Research in Rheumatology, Instituto de Salud Carlos III, European Commission, Servicio Cántabro de Salud, Instituto de Investigación Marqués de Valdecilla, Xunta de Galicia, Scleroderma and Raynaud's UK, Versus Arthritis, Remuzgo-Martínez, Sara, Atienza-Mateo, Belén, Ocejo-Vinyals, J. Gonzalo, Pulito-Cueto, Verónica, Prieto-Peña, Diana, Genre, Fernanda, Márquez, Ana, Llorca, Javier, Mora Cuesta, Víctor M., Fernández, David Iturbe, Riesco, Laura, Ortego-Centeno, Norberto, Pérez Gómez, Nair, Mera, Antonio, Martínez Barrio, Julia, López Longo, Francisco Javier, Lera-Gómez, Leticia, Moriano, Clara, Díez, Elvira, Tornero, Eva, Calvo-Alén, Jaime, Romero-Bueno, Fredeswinda, Sánchez-Pernaute, Olga, Nuño, Laura, Bonilla, Gema, Grafia, Ignacio, Prieto-González, Sergio, Narváez, Javier, Trallero-Araguas, Ernesto, Selva-O'Callaghan, Albert, Gualillo, Oreste, Martín, Javier, Cabagna, Lorenzo, Catañeda, Santos, Cifrian, José M., Renzoni, Elizabetta A., López-Mejías, Raquel, González Gay, M. A., Foundation for Research in Rheumatology, Instituto de Salud Carlos III, European Commission, Servicio Cántabro de Salud, Instituto de Investigación Marqués de Valdecilla, Xunta de Galicia, Scleroderma and Raynaud's UK, Versus Arthritis, Remuzgo-Martínez, Sara, Atienza-Mateo, Belén, Ocejo-Vinyals, J. Gonzalo, Pulito-Cueto, Verónica, Prieto-Peña, Diana, Genre, Fernanda, Márquez, Ana, Llorca, Javier, Mora Cuesta, Víctor M., Fernández, David Iturbe, Riesco, Laura, Ortego-Centeno, Norberto, Pérez Gómez, Nair, Mera, Antonio, Martínez Barrio, Julia, López Longo, Francisco Javier, Lera-Gómez, Leticia, Moriano, Clara, Díez, Elvira, Tornero, Eva, Calvo-Alén, Jaime, Romero-Bueno, Fredeswinda, Sánchez-Pernaute, Olga, Nuño, Laura, Bonilla, Gema, Grafia, Ignacio, Prieto-González, Sergio, Narváez, Javier, Trallero-Araguas, Ernesto, Selva-O'Callaghan, Albert, Gualillo, Oreste, Martín, Javier, Cabagna, Lorenzo, Catañeda, Santos, Cifrian, José M., Renzoni, Elizabetta A., López-Mejías, Raquel, and González Gay, M. A.
- Abstract
Objective: To investigate the human leukocyte antigen (HLA) association with anti-synthetase syndrome (ASSD). Methods: We conducted the largest immunogenetic HLA-DRB1 and HLA-B study to date in a homogeneous cohort of 168 Caucasian patients with ASSD and 486 ethnically matched healthy controls by sequencing-based-typing. Results: A statistically significant increase of HLA-DRB1*03:01 and HLA-B*08:01 alleles in patients with ASSD compared to healthy controls was disclosed (26.2% versus 12.2%, P = 1.56E–09, odds ratio–OR [95% confidence interval–CI] = 2.54 [1.84–3.50] and 21.4% versus 5.5%, P = 18.95E–18, OR [95% CI] = 4.73 [3.18–7.05]; respectively). Additionally, HLA-DRB1*07:01 allele was significantly decreased in patients with ASSD compared to controls (9.2% versus 17.5%, P = 0.0003, OR [95% CI] = 0.48 [0.31–0.72]). Moreover, a statistically significant increase of HLA-DRB1*03:01 allele in anti-Jo-1 positive compared to anti-Jo-1 negative patients with ASSD was observed (31.8% versus 15.5%, P = 0.001, OR [95% CI] = 2.54 [1.39–4.81]). Similar findings were observed when HLA carrier frequencies were assessed. The HLA-DRB1*03:01 association with anti-Jo-1 was unrelated to smoking history. No HLA differences in patients with ASSD stratified according to the presence/absence of the most representative non-anti-Jo-1 anti-synthetase autoantibodies (anti-PL-12 and anti-PL-7), arthritis, myositis or interstitial lung disease were observed. Conclusions: Our results support the association of the HLA complex with the susceptibility to ASSD.
- Published
- 2021
7. Intragastric device
- Author
-
Castillo Suescun, Federico José, Crespo García, Javier, Rodríguez Sanjuán, Juan Carlos, Sancibrián Herrera, Ramón, Oficina Española de Patentes y Marcas (OEPM), Servicio Cántabro de Salud, and Universidad de Cantabria
- Abstract
Dispositivo intragástrico destinado ser introducido en el interior de una cavidad gástrica para restringir su capacidad. Para contribuir a una óptima adaptación, su diseño está basado en el principio de flotabilidad neutra. El dispositivo comprende un núcleo interno y un recubrimiento externo. El núcleo interno está conformado por una cámara (1) cerrada y una primera válvula (4) que conecta el interior de la cámara (1) con el exterior, y a través de la cual se introduce un fluido a presión en el interior de dicha cámara (1). El recubrimiento externo comprende una primera cavidad (5), en la que se aloja el núcleo, y una segunda válvula (7), por la cual se introduce un volumen de fluido en el espacio libre de la cavidad no ocupado por la cámara (1). Dicho fluido de la primera cavidad (5) está a una presión diferente a la del fluido introducido en la cámara (1). Solicitud Internacional: PCT/ES2022/070433 (06.07.2022) Nº Pub. Solicitud Internacional: WO2023/281147A1 (12.01.2023)
- Published
- 2022
8. Dispositivo reposabrazos para cirugía endoscópica
- Author
-
Lobo Duro, David, Sancibrián Herrera, Ramón, Mesones Madrazo, Ángela, Oficina Española de Patentes y Marcas (OEPM), Servicio Cántabro de Salud, and Universidad de Cantabria
- Abstract
Solicitud: 202130841 (26.04.2021) Nº Pub. de Solicitud: ES1271826U (28.06.2021) Nº de Modelo de Utilidad: ES1271826Y (07.10.2021)
- Published
- 2021
9. Optical device for identifying tumour regions
- Author
-
Fernández Luna, José Luis, Martín Láez, Rubén, Velásquez Rodríguez, Carlos José, Moreno Gracia, Fernando, González Fernández, Francisco, Franco Pérez, Alfredo, Vidal Sánchez, Verónica, Organización Mundial de la Propiedad Intelectual (OMPI/WIPO), Fundación Instituto de Investigación Marqués de Valdecilla, Servicio Cántabro de Salud, Universidad de Cantabria, and Fotoglass
- Abstract
The present invention relates to an optical device for identifying tumour regions in different organs, such as the brain. The device comprises: a plurality of chips, each chip having a metallic nanostructured surface; means for receiving a tissue sample to be analysed and depositing it on one of the chips when the chip is disposed in an illumination area; a light source configured to provide a light beam to illuminate the chip on which the sample has been deposited; and a spectrometer for receiving a light beam reflected by the chip, configured to extract the spectral response of the light reflected by same. The spectral response depends on the refractive index of the tissue sample analysed, which, in turn, depends on whether the tissue is necrotic, tumoural or peritumoural. RESUMEN: La presente invención se refiere a un dispositivo óptico para identificación de regiones tumorales en distintos órganos, como por ejemplo el cerebro. El dispositivo comprende una pluralidad de chips, cada chip con una superficie metálica nanoestructurada, medios para recibir una muestra de tejido a analizar y para depositarla sobre uno de los chips cuando esté situado en una zona de iluminación, una fuente de luz configurada para proporcionar un haz de luz para iluminar el chip sobre el que se ha depositado la muestra, un espectrógrafo para recibir un haz de luz reflejado por dicho chip configurado para extraer la respuesta espectral de la luz reflejada por el mismo. La respuesta espectral depende del índice de refracción de la muestra de tejido analizado, que a su vez depende de si el tejido es un tejido necrosado, tumoral o peritumoral. Solicitud Internacional: PCT/ES2021/070451 (18.06.2020) Nº Pub. Solicitud Internacional: WO2021/260245A1 (30.12.2021)
- Published
- 2021
10. Dispositivo intragástrico
- Author
-
Castillo Suescun, Federico José, Crespo García, Javier, Sancibrián Herrera, Ramón, Rodríguez Sanjuán, Juan Carlos, Oficina Española de Patentes y Marcas (OEPM), Servicio Cántabro de Salud, and Universidad de Cantabria
- Abstract
Dispositivo intragástrico destinado ser introducido en el interior de una cavidad gástrica para restringir su capacidad. Para contribuir a una óptima adaptación, su diseño está basado en el principio de flotabilidad neutra. El dispositivo comprende un núcleo interno y un recubrimiento externo. El núcleo interno está conformado por una cámara (1) cerrada y una primera válvula (4) que conecta el interior de la cámara (1) con el exterior, y a través de la cual se introduce un fluido a presión en el interior de dicha cámara (1). El recubrimiento externo comprende una primera cavidad (5), en la que se aloja el núcleo, y una segunda válvula (7), por la cual se introduce un volumen de fluido en el espacio libre de la cavidad no ocupado por la cámara (1). Dicho fluido de la primera cavidad (5) está a una presión diferente a la del fluido introducido en la cámara (1). Solicitud: 202130649 Nº Pub. de Solicitud: ES2933224A1 (02.02.2023)
- Published
- 2021
11. Dispositivo óptico para identificación de regiones tumorales
- Author
-
Fernández Luna, José Luis, Martino González, Juan, Velásquez Rodríguez, Carlos José, Moreno Gracia, Fernando, González Fernández, Francisco, Vidal Sánchez, Verónica, Franco Pérez, Alfredo, Oficina Española de Patentes y Marcas (OEPM), Fundación Instituto de Investigación Marqués de Valdecilla, Servicio Cántabro de Salud, Universidad de Cantabria, and Fotoglass
- Abstract
Solicitud: U202031383 (26.06.2020) Nº Pub. de Solicitud: ES1255024U (27.10.2020) Nº de Modelo de Utilidad: ES1255024 Y (15.01.2021)
- Published
- 2020
12. Sistema endoscópico de orientación espacial
- Author
-
Viera Artiles, Jaime, Valdiande Gutiérrez, José Julián, López Higuera, José Miguel, Organización Mundial de la Propiedad Intelectual (OMPI/WIPO), Servicio Cántabro de Salud, and Universidad de Cantabria
- Abstract
The present invention relates to a system for improving spatial orientation in endoscopic surgery, designed to control the spatial position of the endoscope with respect to a reference position. RESUMEN: La presente invención se refiere a un sistema para mejorar la orientación espacial en cirugía endoscópica, configurado para controlar la posición espacial del endoscopio respecto a una posición de referencia. Solicitud: PCT/ES2020/070449 (10.07.2020) Nº de Publicación: WO2021/009401A1 (21.01.2021)
- Published
- 2020
13. Máscara de protección para la manipulación nasal
- Author
-
Viera Artiles, Jaime, Valdiande Gutiérrez, José Julián, López Higuera, José Miguel, Oficina Española de Patentes y Marcas (OEPM), Servicio Cántabro de Salud, and Universidad de Cantabria
- Abstract
Solicitud: 202030765 (30.04.2020) Nº Pub. de Solicitud: ES1247959U (17.06.2020) Nº de Modelo de Utilidad: ES1247959Y (07.09.2020)
- Published
- 2020
14. Sistema endoscópico de orientación espacial
- Author
-
Viera Artiles, Jaime, Valdiande Gutiérrez, José Julián, López Higuera, José Miguel, Oficina Española de Patentes y Marcas (OEPM), Servicio Cántabro de Salud, and Universidad de Cantabria
- Abstract
Sistema endoscópico que comprende una lente tubular rígida con un canal para el paso de luz a través de fibra óptica, configurada para introducirse en una cavidad a través de un orificio o incisión cutánea y cuya función es captar y transmitir la imagen de la cavidad iluminada; una cámara conectada a un extremo de la lente tubular configurada para digitalizar la imagen obtenida a través de dicha lente tubular; una fuente de luz conectada también a la lente tubular por el extremo que se conecta a la cámara; un receptor de video conectado a la cámara a través del cual se recoge la señal proveniente de la misma; y una pantalla que permite visualizar la imagen saliente del receptor de video, estando el sistema caracterizado por que comprende además: - un sensor inercial que comprende al menos un acelerómetro de 3 ejes y un giroscopio de 2 ejes, estando el sensor inercial configurado para, a partir de los datos de aceleración angular obtenidos por el acelerómetro y de velocidad angular obtenidos por el giroscopio, proporcionar la orientación del sensor inercial a través de los ángulos de alabeo (rotación en el eje X) y cabeceo (rotación en el eje Y) que se corresponden con los ángulos de giro del endoscopio (cámara 10 + lente tubular 11) debido a los giros de muñeca del cirujano que está manejando el endoscopio, tal que dicho sensor inercial debe estar situado en la cámara (en su interior o en su superficie, a su entrada o salida) o en sus proximidades (a su entrada o salida), de forma que no interfiera al cirujano durante su utilización, y tal que el eje X del sensor inercial debe situarse de manera paralela al eje longitudinal de la lente tubular, el eje Y del sensor inercial de manera paralela al eje transversal de la lente tubular y el eje Z del sensor inercial de manera paralela a la vertical del endoscopio(cámara 10 +lente tubular 11); - un sistema informático que comprende un puerto de recepción de datos del sensor inercial conectado a dicho sensor inercial; una capturadora de video configurada para captarla señal de video de salida del receptor de video que recoge la señal proveniente de la cámara; una salida de video del mismo formato que el video de entrada recogido en la capturadora de video conectada a la pantalla y un puerto de conexión conectado a un dispositivo de interacción humana y que recoge los datos de dicho dispositivo; - un dispositivo de interacción humana configurado para interactuar con el software del sistema informático y comandar las funcionalidades pertinentes de dicho sistema informático. Solicitud: U201931231 (18.07.2019) Nº Pub. de Solicitud: ES1235420U (30.09.2019) Nº de Modelo de Utilidad: ES123542Y (23.12.2019)
- Published
- 2019
15. System and device for positioning medical needles
- Author
-
Prada Gómez, Pedro José, Raba Díez, Juan Ignacio, Rodríguez Cobo, Luis, Valdiande Gutiérrez, José Julián, Cobo García, Adolfo, Conde Portilla, Olga María, López Higuera, José Miguel, Organización Mundial de la Propiedad Intelectual (OMPI/WIPO), Servicio Cántabro de Salud, and Universidad de Cantabria
- Abstract
A system for inserting needles into a body, comprising: a guide plate comprising a plurality of apertures, each aperture being configured to receive a needle to be inserted into a body, wherein at least some apertures of said plurality of apertures have a respective detector associated thereto, each detector comprising a resonant circuit for detecting the presence of a needle inserted into a respective aperture, said resonant circuit being configured to modify its resonant frequency when the needle is inserted into the aperture; a probe for measuring, together with the detector comprised in an aperture, the penetration depth of a needle inserted into said aperture, each detector being configured to track changes in its resonant frequency produced when said probe is inserted along the needle in turn inserted into the aperture; and control electronics for interrogating each detector and for determining the presence or absence of a needle in a corresponding aperture and for determining the penetration depth of a detected needle from said tracked changes in the resonant frequency of a corresponding detector. Solicitud Internacional: PCT/EP2018/057681 (26.03.2018) Nº Pub. Solicitud Internacional: WO2018/178031A1 (04.10.2018) Solicitud Europea: 17382162.0 (30.03.2017) Nº Pub. Solicitud Europea: EP3381513A1 (03.10.2018) Nº de Patente Europea: EP3600547B1 (23.12.2020) Traducción de patente europea (España): ES2845000T3 (23.07.2021)
- Published
- 2018
16. Cartridge, device and method for detecting, capturing, identifying and counting circulating tumour cells
- Author
-
Moreno Gracia, Fernando, González Fernández, Francisco, Barreda Gómez, Ángela Inmaculada, Juarros Laskurain, Aritz, Otaduy del Paso, Deitze, Merino Álvarez, Santos, Fernández Luna, José Luis, Franco Pérez, Alfredo, Aguirre Yagüe, Francisco, Organización Mundial de la Propiedad Intelectual (OMPI/WIPO), Universidad de Cantabria, Servicio Cántabro de Salud, Fundación Instituto de Investigación Marqués de Valdecilla, Fundación Tekniker, and Cellbiocan S. L.
- Abstract
A cartridge, device and method for detecting, capturing, identifying and counting circulating tumour cells, specifically relating to a cartridge which enables the capture and optionally recovery of circulating tumour cells (CTCs), a device for detecting, identifying and counting CTCs and a method for detecting, identifying and counting CTCs. Solicitud Internacional: PCT/EP2018/070724 (31.07.2018) Nº Pub. Solicitud Internacional: WO2019/025437A1 (07.02.2019)
- Published
- 2018
17. Method for predicting the therapeutic response to antipsychotic drugs
- Author
-
Sainz Maza, Jesús Vicente, Crespo Facorro, Benedicto, Organización Mundial de la Propiedad Intelectual (OMPI/WIPO), Consejo Superior de Investigaciones Científicas, Universidad de Cantabria, CIBER: Centro de Investigación Biomédica en Red, and Servicio Cántabro de Salud
- Abstract
The present invention discloses a method for predicting, before treatment, the individual clinical response to antipsychotic medication in subjects suffering from psychosis. This method is based on a gene expression profile that is useful to predict the therapeutic response to antipsychotics in drug-naïve patients. Particularly, the gene signature proposed in the invention comprises six-genes (SLC9A3, HMOX1, SLC22A16, LOC284581, PF4V1 and GSTT1) which expression profile, preferably measured in blood samples collected from the patient, provides useful information to predict the clinical response to antipsychotics in psychotic patients, more preferably in schizophrenia patients, before treatment. Solicitud Internacional: PCT/EP2018/057761 (27.03.2018) Nº Pub. Solicitud Internacional: WO2018/178071A1 (04.10.2018)
- Published
- 2018
18. Method for predicting the clinical response to a treatment with anti-inflammatory agents
- Author
-
Fernández Luna, José Luis, Martínez Taboada, Víctor Manuel, López Hoyos, Marcos, Torices del Val, Silvia, Muñoz Cacho, Pedro, Varela Egocheaga, Ignacio, Balsa Criado, Alejandro, Marsal Barril, Sara, Juliá Cano, Antonio, Organización Mundial de la Propiedad Intelectual (OMPI/WIPO), Fundación Instituto de Investigación Marqués de Valdecilla, Servicio Cántabro de Salud, Universidad de Cantabria, and Fundació Hospital Universitari Vall D'Hebron-Institut de Recerca
- Abstract
The present invention relates to the use of allelic variants of human TLR10, including the allelic variant of human TLR10, I473T, as biomarkers for predicting gravity or prognosis in inflammatory diseases, including rheumatoid arthritis, and/or for predicting the response to a treatment using anti-inflammatory agents such as anti-TNFα agents. RESUMEN: La presente invención se refiere al uso de variantes alélicas de TLR10 humano, incluyendo a la variante alélica de TLR10 humano I473T: como biomarcador para predecir la gravedad o el pronóstico en enfermedades inflamatorias, incluyendo la artritis reumatoide y/o para predecir la respuesta a un tratamiento con agentes antiinflamatorios, tales como agentes anti-TNFα. Solicitud Internacional: PCT/ES2017/000089 (07.07.2017) Nº Pub. Solicitud Internacional: WO2018/020060A1 (01.02.2018)
- Published
- 2017
19. Método para predecir la respuesta clínica a un tratamiento con agentes antiinflamatorios
- Author
-
Fernández Luna, José Luis, Martínez Taboada, Víctor Manuel, López Hoyos, Marcos, Torices del Val, Silvia, Muñoz Cacho, Pedro, Varela Egocheaga, Ignacio, Balsa Criado, Alejandro, Marsal Barril, Sara, Juliá Cano, Antonio, Oficina Española de Patentes y Marcas (OEPM), Fundación Instituto de Investigación Marqués de Valdecilla, Servicio Cántabro de Salud, Universidad de Cantabria, FIBHULP, and VHIR
- Abstract
La presente invención se refiere al uso de variantes alélicas de TLR10 humano, incluyendo a la variante alélica de TLR10 humano I473T, como biomarcador para predecir la gravedad o el pronóstico en enfermedades inflamatorias, incluyendo la artritis reumatoide y/o para predecir la respuesta a un tratamiento con agentes antiinflamatorios, tales como agentes anti-TNF [al]. Solicitud: 201600636 (26.07.2016) Nº Pub. de Solicitud: ES2656587A1 (27.02.2018) Nº de Patente: ES2656587B1(11.12.2018)
- Published
- 2016
20. Mango ergonómico y sistema para instrumento de cirugía endoscópica o laparoscópica
- Author
-
Sancibrián Herrera, Ramón, Laporte Azcue, Marta, Gutiérrez Díaz, María Cruz, Redondo Figuero, Carlos, Benito González, María Asunción, Manuel Palazuelos, José Carlos, Oficina Española de Patentes y Marcas (OEPM), Universidad de Cantabria, and Servicio Cántabro de Salud
- Abstract
Mango para una herramienta distal de cirugía endoscópica o laparoscópica, que comprende una empuñadura, una rueda de orientación y una palanca de accionamiento, de tal forma que la palma de la mano y los dedos corazón, anular y meñique rodean y sujetan firmemente la empuñadura, mientras que el dedo pulgar se apoya sobre la palanca de accionamiento, y el dedo índice se apoya sobre la rueda de orientación, tal que la palanca de accionamiento comprende una parte visible, y una parte no visible, donde la parte visible de la palanca de accionamiento está situada en la zona superior de la empuñadura, y su movimiento está comprendido a lo largo del eje longitudinal de la herramienta, presentando diferentes posiciones que conllevan diferentes grados de apertura de la herramienta distal, y tal que una de las direcciones de accionamiento requiere fuerza por parte del portador para conseguir el movimiento de la herramienta distal, mientras que la dirección opuesta no requiere fuerza, y donde la parte no visible de la palanca de accionamiento presenta dos aberturas enfrentadas y configuradas para situar un pivote que sirve a la palanca de accionamiento de sostén en el movimiento, de tal forma que el eje longitudinal del pivote es perpendicular al movimiento de la palanca de accionamiento, y donde además dicha parte no visible de la palanca de accionamiento comprende en su interior un elemento de accionamiento cuyo eje longitudinal es paralelo al eje longitudinal del pivote. Solicitud: 201500530 (15.07.2015) Nº Pub. de Solicitud: ES2562350A1 (03.03.2016) Nº de Patente: ES2562350B2 (28.09.2016)
- Published
- 2015
21. Device and method for detecting biomarkers
- Author
-
Moreno Gracia, Fernando, González Fernández, Francisco, Barreda Gómez, Ángela Inmaculada, Díez Ahedo, Ruth, Otaduy del Paso, Deitze, Merino Álvarez, Santos, Fernández Luna, José Luis, Talamillo Cancelo, Ana, Organización Mundial de la Propiedad Intelectual (OMPI/WIPO), Universidad de Cantabria, Servicio Cántabro de Salud, Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Fundación Tekniker, and Cellbiocan, S.L.
- Abstract
The invention relates to a biosensor for detecting the concentration or quantity of at least one biomarker present in a sample of fluid, said biosensor comprising: a chip having a substrate on which a metal layer has been deposited, said metal layer having at least one nanostructure designed to produce LSPR when subjected to optical radiation of a determined spectral range; and a resonant cavity delimited by two surfaces that act as a mirror, wherein one of the two surfaces is the metal layer having the nanostructuring. The metal layer having at least one nanostructure is biofunctionalised using at least one biomolecule that recognises the at least one biomarker. In exposing the chip to optical radiation when the sample is in contact with the chip, the concentration or quantity of the biomarker present in the sample in measured, by comparing the spectral response of the light at the output of the chip with a previously determined spectral pattern. The spectral response responds to the combined effect of LSPR in the plasmonic nanostructure and the resonance of the resonant cavity. RESUMEN: RESUMEN: Un biosensor para detectar la concentración o cantidad de al menos un biomarcador presente en una muestra de un fluido. Comprende: un chip que comprende: un sustrato sobre el que se ha depositado una capa de metal con al menos una nanoestructura diseñada para producir LSPR cuando es sometida a una radiación óptica de un determinado rango espectral; y una cavidad resonante delimitada por dos superficies que actúan como espejo, donde una de las dos superficies es la capa de metal con nanoestructura. La capa de metal con al menos una nanoestructura está biofuncionalizada con al menos una biomoléculaque reconoce dicho al menos un biomarcador. Al exponer el chip a radiación óptica cuando la muestra está en contacto con el chip, se mide la concentración o cantidad de dicho biomarcador presente en la muestra, mediante la comparación de la respuesta espectral de la luz a la salida del chip con un patrón espectral previamente determinado. La respuesta espectral responde al efecto combinado de LSPR en la nanoestructura plasmónica y de la resonancia de la cavidad resonante. Solicitud Internacional: PCT/ES2014/070215 (21.03.2014) Nº Pub. Solicitud Internacional: WO2015/140362A1 (24.09.2015) Solicitud Europea: 14721426.6 (21.03.2014) Nº Pub. Solicitud Europea: EP3121587A1 (25.01.2017)
- Published
- 2014
22. HLA and non-HLA genes in Behçet¿s disease: a multicentric study in the Spanish population
- Author
-
Miguel A. González-Gay, P. Fanlo, Genaro Graña-Gil, María Francisca González-Escribano, Norberto Ortego-Centeno, Ana Celia Barnosi-Marín, Javier Martín, Juan Sánchez-Bursón, Gerard Espinosa, Marta Conde-Jaldón, Roser Solans, Antonio Núñez-Roldán, Teresa Camps, José Raúl García-Lozano, M.A. Montes-Cano, María Jesús Castillo-Palma, Lourdes Ortiz-Fernández, Santos Castañeda, [Montes Cano,A, Conde-Jaldón,M, García-Lozano,J, Ortiz-Fernández,L, Núñez-Roldán,A, González-Escribano,MF] Servicio de Inmunología, IBiS, Hospital Universitario Virgen del Rocío/CSIC/ Universidad de Sevilla, Spain. [Ortego-Centeno,N] Servicio de Medicina Interna, Hospital Clínico San Cecilio, Granada, Spain. [Castillo-Palma,MJ] Servicio de Medicina Interna, Hospital Universitario Virgen del Rocío, Sevilla, Spain. [Espinosa,G] Servicio de Enfermedades Autoinmunes, Hospital Clinic, Barcelona, Spain. [Graña-Gil,G] Servicio de Reumatología, CHU A Coruña, Spain. [González-Gay,MA] Servicio de Reumatología, Hospital Marques de Valdecilla, Santander, Spain. [Barnosi-Marín,AC] Servicio de Medicina Interna, Hospital Torrecárdenas, Almería, Spain. [Solans,R] Servicio de Medicina Interna, Hospital Vall d’Hebron, Barcelona, Spain. [Fanlo,P] Servicio de Medicina Interna, Hospital Virgen del Camino, Pamplona, Spain. [Camps,T] Servicio de Medicina Interna, Hospital Carlos Haya, Málaga, Spain. [Castañeda,S] Servicio de Reumatología, Hospital de la Princesa, Madrid, Spain. [Sánchez-Bursón,J] Servicio de Reumatología, Hospital de Valme, Sevilla, Spain. [Martín,J] IPB López Neyra, Granada, Spain., Fondo de Investigaciones Sanitarias (10/1701), Fondos FEDER, Plan Andaluz de Investigación (CTS-0197 and CTS-180), Red Enfermedades Inflamatorias y Reumáticas RD08/0075/0013 and Consejería de Salud de la Junta de Andalucía (PI0411/2010). LOF is the recipient of a fellowship (FI11/00547). The authors thank Asociación Andaluza de Enfermedades Autoinmunes (AADEA) and all patients and donors enrolled in the present study for their cooperation. Also, the authors thank the following public Spanish institutions for their participation in this study: Servicio Andaluz de Salud (Hospitales Torrecárdenas, Almería, Clínico San Cecilio, Granada, and Carlos Haya, Málaga, and Virgen del Rocío and Valme, Sevilla), Servei Catalá de la Salut (Clinic and Vall d’Hebron hospitals, Barcelona), Servizo Galego de Saude (Complejo Hospitalario Universitario, A Coruña), Servicio Cántabro de Salud (Hospital Marqués de Valdecilla, Santander), Servicio Navarro de Salud (Hospital Virgen del Camino, Pamplona), Servicio Montes-Cano et al. Arthritis Research & Therapy 2013, 15:R145
- Subjects
Male ,Antígeno HLA-B35 ,Candidate gene ,Genome-wide association study ,Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings] ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Glycoproteins::Membrane Glycoproteins::Histocompatibility Antigens Class I::HLA-A Antigens [Medical Subject Headings] ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings] ,Chemicals and Drugs::Biological Factors::Antigens::Antigens, Surface::Histocompatibility Antigens::HLA Antigens::HLA-B Antigens::HLA-B35 Antigen [Medical Subject Headings] ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,Receptores de Interleucina ,Gene Frequency ,Risk Factors ,HLA Antigens ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Models, Theoretical::Models, Statistical::Logistic Models [Medical Subject Headings] ,Immunology and Allergy ,Diseases::Stomatognathic Diseases::Mouth Diseases::Behcet Syndrome [Medical Subject Headings] ,Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings] ,Genetics ,education.field_of_study ,Behcet Syndrome ,Antígenos HLA-B ,Antígenos HLA-A ,Middle Aged ,Interleukin-10 ,Chemicals and Drugs::Biological Factors::Antigens::Antigens, Surface::Histocompatibility Antigens::HLA Antigens::HLA-B Antigens [Medical Subject Headings] ,Chemicals and Drugs::Biological Factors::Antigens::Antigens, Surface::Histocompatibility Antigens::HLA Antigens::HLA-B Antigens::HLA-B51 Antigen [Medical Subject Headings] ,HLA-B51 Antigen ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Immunologic::Receptors, Cytokine::Receptors, Interleukin [Medical Subject Headings] ,Female ,Chemicals and Drugs::Biological Factors::Antigens::Antigens, Surface::Histocompatibility Antigens::HLA Antigens [Medical Subject Headings] ,Interleucina-10 ,Phenomena and Processes::Genetic Phenomena::Genotype [Medical Subject Headings] ,Antígeno HLA-B51 ,Research Article ,HLA-B57 antigen ,Adult ,Antígeno HLA-B57 ,Genotype ,Immunology ,Population ,Check Tags::Male [Medical Subject Headings] ,Single-nucleotide polymorphism ,Human leukocyte antigen ,Biology ,Polymorphism, Single Nucleotide ,Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Susceptibility::Genetic Predisposition to Disease [Medical Subject Headings] ,Rheumatology ,IL23R protein, human ,Named Groups::Persons::Age Groups::Adult [Medical Subject Headings] ,HLA-B Antigens ,Humans ,Genetic Predisposition to Disease ,education ,Allele frequency ,Phenomena and Processes::Genetic Phenomena::Genetic Variation::Polymorphism, Genetic::Polymorphism, Single Nucleotide [Medical Subject Headings] ,HLA-A Antigens ,Antígeno HLA ,Receptors, Interleukin ,Minor allele frequency ,Logistic Models ,Check Tags::Female [Medical Subject Headings] ,Spain ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Cytokines::Interleukins::Interleukin-10 [Medical Subject Headings] ,HLA-B35 Antigen ,Phenomena and Processes::Genetic Phenomena::Gene Frequency [Medical Subject Headings] ,Genome-Wide Association Study - Abstract
Introduction According to genome wide association (GWA) studies as well as candidate gene approaches, Behçet’s disease (BD) is associated with human leukocyte antigen (HLA)-A and HLA-B gene regions. The HLA-B51 has been consistently associated with the disease, but the role of other HLA class I molecules remains controversial. Recently, variants in non-HLA genes have also been associated with BD. The aims of this study were to further investigate the influence of the HLA region in BD and to explore the relationship with non-HLA genes recently described to be associated in other populations. Methods This study included 304 BD patients and 313 ethnically matched controls. HLA-A and HLA-B low resolution typing was carried out by PCR-SSOP Luminex. Eleven tag single nucleotide polymorphisms (SNPs) located outside of the HLA-region, previously described associated with the disease in GWA studies and having a minor allele frequency in Caucasians greater than 0.15 were genotyped using TaqMan assays. Phenotypic and genotypic frequencies were estimated by direct counting and distributions were compared using the χ2 test. Results In addition to HLA-B*51, HLA-B*57 was found as a risk factor in BD, whereas, B*35 was found to be protective. Other HLA-A and B specificities were suggestive of association with the disease as risk (A*02 and A*24) or protective factors (A*03 and B*58). Regarding the non-HLA genes, the three SNPs located in IL23R and one of the SNPs in IL10 were found to be significantly associated with susceptibility to BD in our population. Conclusion Different HLA specificities are associated with Behçet’s disease in addition to B*51. Other non-HLA genes, such as IL23R and IL-10, play a role in the susceptibility to the disease., This work was supported by Fondo de Investigaciones Sanitarias (10/1701), Fondos FEDER, Plan Andaluz de Investigación (CTS-0197 and CTS-180), Red Enfermedades Inflamatorias y Reumáticas RD08/0075/0013 and Consejería de Salud de la Junta de Andalucía (PI0411/2010). LOF is the recipient of a fellowship (FI11/00547).
- Published
- 2013
- Full Text
- View/download PDF
23. Métodos de selección de terapia de linfoma cutáneo de células T
- Author
-
Piris Pinilla, Miguel Ángel, Vaqué Díez, José Pedro, Martínez Magunacelaya, Nerea, Ortiz Romero, Pablo Luis, Sánchez-Beato Gómez, Margarita, Organización Mundial de la Propiedad Intelectual (OMPI/WIPO), Fundación Marqués de Valdecilla, Fundación de Investigación Biomédica del Hospital Universitario Puerta de Hierro de Majadahonda, Fundación para la Investigación Biomédica del Hospital 12 de Octubre, Fundación Científica de la Asociación Española Contra el Cáncer, and Servicio Cántabro de Salud
- Abstract
The invention relates to a method for selecting a therapy for the treatment of a patient with cutaneous T-cell lymphoma (LCCT), said method comprising determining the presence of a mutation in the PLCG1 gene in a sample from said patient, and selecting the therapy according to the mutational profile of the patient. RESUMEN: El método para seleccionar una terapia para el tratamiento de un paciente con linfoma cutáneo de células T (LCCT) comprende determinar en una muestra de dicho paciente la presencia de una mutación en el gen PLCG1 y seleccionar la terapia en función del perfil mutacional del paciente. Solicitud Internacional: PCT/ES2013/070795 (13.11.2013) Nº Pub. Solicitud Internacional: WO2014/076344A1 (22.05.2014)
- Published
- 2013
24. Sistema de oclusión y fijación alrededor de trocar de laparoscopia
- Author
-
Schneider Fontán, José, Oficina Española de Patentes y Marcas (OEPM), Universidad de Cantabria, and Servicio Cántabro de salud
- Abstract
Un sistema de oclusión y fijación de un trocar para cirugía laparoscópica, que comprende un hilo y un dispositivo de fijación que a su vez comprende una perforación. El dispositivo de fijación está configurado para que los extremos de dicho hilo atraviesen dicha perforación, y queden fijados por dicho dispositivo de fijación. El sistema de oclusión y fijación está configurado para, durante su uso, y una vez que dicho hilo ha servido de sutura de una cavidad corporal alrededor de un trocar: enganchar uno de los extremos del hilo en al menos un punto de anclaje de dicho trocar, de forma que al tirar de los dos extremos del hilo para efectuar el cierre de la sutura, el trocar es inmovilizado por dicha sutura, comprimiendo de forma hermética el tejido corporal, y fijar los dos extremos del hilo mediante dicho dispositivo de fijación. Solicitud: 201200476 (02.05.2012) Nº Pub. de Solicitud: ES2403026A1 (13.05.2013) Nº de Patente: ES2403026B1 (16.12.2013)
- Published
- 2012
25. Métodos de selección de terapia de linfoma cutáneo de células T
- Author
-
Piris Pinilla, Miguel Ángel, Vaqué Díez, José Pedro, Martínez Magunacelaya, Nerea, Ortiz Romero, Pablo Luis, Sánchez-Beato Gómez, Margarita, Oficina Española de Patentes y Marcas (OEPM), Fundación de Investigación Biomédica del Hospital Universitario Puerta de Hierro de Majadahonda, Fundación para la Investigación Biomédica del Hospital 12 de Octubre, Fundación Científica de la Asociación Española Contra el Cáncer, Servicio Cántabro de Salud, and Fundación Instituto de Investigación Marqués de Valdecilla
- Abstract
El método para seleccionar una terapia para el tratamiento de un paciente con linfoma cutáneo de células T (LCCT) comprende determinar en una muestra de dicho paciente la presencia de una mutación en al menos un gen seleccionado del grupo formado por los genes PLCG1, CCR4, IL-6ST, JAK1, JAK3 y cualquier combinación de los mismos, y seleccionar la terapia en función del perfil mutacional del paciente. Solicitud: 201231760 (14.11.2012) Nº Pub. de Solicitud: ES2469265A1 (17.06.2014) Nº de Patente: ES2469265B1 (06.03.2015)
- Published
- 2012
26. Radioligand Therapy in Lymphoma: Past, Present, and Future.
- Author
-
Almeida LS, Delgado Bolton RC, Heringer VC, de Souza Medina S, and Etchebehere E
- Subjects
- Humans, Antibodies, Monoclonal therapeutic use, History, 20th Century, History, 21st Century, Iodine Radioisotopes therapeutic use, Yttrium Radioisotopes therapeutic use, Lymphoma radiotherapy, Lymphoma diagnostic imaging, Radioimmunotherapy methods, Radiopharmaceuticals therapeutic use
- Abstract
In the1980s, radiolabeled cells helped understand the pathology of hemato-oncology. In the 1990s, preclinical trials evaluated radiolabeled immunotherapy with monoclonal antibodies (MoAbs) such as anti-CD20 agents labeled with Iodine-131 (Bexxar) or Yttrium-90 (Zevalin). Due to the safe and durable responses of radiolabeled MoAbs, the Food and Drug Administration approved these agents in the 2000s. Despite radioimmunotherapy's long journey, its application has recently decreased. This review will discuss the historical timeline of radioimmunotherapy, debate on advantages and difficulties, and explore trials. We will examine future directions of radioligand therapy in hemato-oncology, considering emerging molecules that may become the next theragnostic trend., Competing Interests: Disclosure L.S. Almeida: This study was supported, in part, by the CapesPRInt (Institutional Program for Internationalization) scholarship given to Ludmila Santiago Almeida (reference number: PRINT – 88887.716546/2022-00) by the CAPES (Coordination for the Improvement of Higher Education Personnel) Foundation, within the Brazilian Ministry of Education, Government of Brazil (ludsantiagoalmeida@gmail.com). R.C. Delgado Bolton: rbiolton@gmail.com—Nothing to declare. V.C. Heringer: drv.cabralheringer@gmail.com—Nothing to declare. S. de Souza Medina: souzamedina@gmail.com—Nothing to declare. EE: elba@unicamp.br—CEPID – CancerThera project (FAPESP # 2021/10,265–8) partly supports this study., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
27. Radiotherapy and theranostics: a Lancet Oncology Commission.
- Author
-
Abdel-Wahab M, Giammarile F, Carrara M, Paez D, Hricak H, Ayati N, Li JJ, Mueller M, Aggarwal A, Al-Ibraheem A, Alkhatib S, Atun R, Bello A, Berger D, Delgado Bolton RC, Buatti JM, Burt G, Bjelac OC, Cordero-Mendez L, Dosanjh M, Eichler T, Fidarova E, Gondhowiardjo S, Gospodarowicz M, Grover S, Hande V, Harsdorf-Enderndorf E, Herrmann K, Hofman MS, Holmberg O, Jaffray D, Knoll P, Kunikowska J, Lewis JS, Lievens Y, Mikhail-Lette M, Ostwald D, Palta JR, Peristeris P, Rosa AA, Salem SA, Dos Santos MA, Sathekge MM, Shrivastava SK, Titovich E, Urbain JL, Vanderpuye V, Wahl RL, Yu JS, Zaghloul MS, Zhu H, and Scott AM
- Abstract
Following on from the 2015 Lancet Oncology Commission on expanding global access to radiotherapy, Radiotherapy and theranostics: a Lancet Oncology Commission was created to assess the access and availability of radiotherapy to date and to address the important issue of access to the promising field of theranostics at a global level. A marked disparity in the availability of radiotherapy machines between high-income countries and low-income and middle-income countries (LMICs) has been identified previously and remains a major problem. The availability of a suitably trained and credentialled workforce has also been highlighted as a major limiting factor to effective implementation of radiotherapy, particularly in LMICs. We investigated initiatives that could mitigate these issues in radiotherapy, such as extended treatment hours, hypofractionation protocols, and new technologies. The broad implementation of hypofractionation techniques compared with conventional radiotherapy in prostate cancer and breast cancer was projected to provide radiotherapy for an additional 2·2 million patients (0·8 million patients with prostate cancer and 1·4 million patients with breast cancer) with existing resources, highlighting the importance of implementing new technologies in LMICs. A global survey undertaken for this Commission revealed that use of radiopharmaceutical therapy-other than
131 I-was highly variable in high-income countries and LMICs, with supply chains, workforces, and regulatory issues affecting access and availability. The capacity for radioisotope production was highlighted as a key issue, and training and credentialling of health professionals involved in theranostics is required to ensure equitable access and availability for patient treatment. New initiatives-such as the International Atomic Energy Agency's Rays of Hope programme-and interest by international development banks in investing in radiotherapy should be supported by health-care systems and governments, and extended to accelerate the momentum generated by recognising global disparities in access to radiotherapy. In this Commission, we propose actions and investments that could enhance access to radiotherapy and theranostics worldwide, particularly in LMICs, to realise health and economic benefits and reduce the burden of cancer by accessing these treatments., Competing Interests: Declaration of interests HH serves (unpaid) on an external advisory board of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, on the International Advisory Board of the University of Vienna, on the Scientific Committee of the German Cancer Research Center (DKFZ), on the Board of Trustees of the DKFZ, and on the advisory board of The Lancet Oncology; is remunerated for serving on the Board of Directors of Ion Beam Applications; receives stock options for serving on the Board of Directors of iCAD; and reports research funding to their institution (Memorial Sloan-Kettering Center Support Grant/Core Grant P30 CA008748) from the National Institutes of Health (NIH)–National Cancer Institute (NCI). AA reports funding to their institution from the National Institute for Health and Care Research (NIHR) and the NIH. GB reports research funding to their institution from the Science and Technology Facilities Council UK and reports travel support from International Council Expert Corps. MD reports research funding to their institution from Science and Technology Facilities Council UK and reports travel support from International Council Expert Corps. TE reports honoraria from the University of Washington and the Japanese Society for Radiation Oncology (JASTRO) and reports receiving travel support to attend meetings from JASTRO, the Turkish Society for Radiation Oncology, and the American Society for Radiation Oncology (ASTRO). SGr reports receiving grants from the NCI; reports consulting fees from Lumonus and the Sustainable Dialogue on Peaceful Uses; and has stock options in Harbinger Health. KH reports research funding to their institution from Novartis and Sofie Biosciences; reports consulting fees from Advanced Accelerator Applications, Amgen, AstraZeneca, Bain Capital, Bayer, Boston Scientific, Convergent, Curiun, Debiopharm, EcoR1, Fusion, GE Healthcare, Immedica, Isotopen Technologien Munchen, Janssen, Merck, Molecular Partners, Nvision, POINT Biopharma, Pfizer, Radiopharm Theranostics, Telix, Theragnostics, and Ymabs; reports honoraria for lectures from PeerVoice; serves on paid advisory boards for Fusion and GE Healthcare; reports travel support from Janssen; and has stock options from Sofie Biosciences, Pharma15, Nvision, Convergent, Aktis Oncology, and AdvanCell. MSH reports research funding to their institution from the Prostate Cancer Foundation, the US Department of Defence, Movember, and the Peter MacCallum Foundation; reports clinical trial funding to their institution from Bayer and Isotopia; reports clinical trial support to their institution from the Australian Nuclear Science and Technology Organisation; reports consulting fees from Merck Sharp & Dohme and Novartis; reports speaker fees from Janssen and AstraZeneca; reports fees to their institution for serving on the advisory board on Novartis; reports unremunerated participation in the Scientific Committee at the Australian Friends of Sheba; and is supported by a National Health and Medical Research Council (NHMRC) Investigator grant. DJ reports royalties from Elekta Oncology System, Precision X-ray System, and Modus Medical; reports license of technology to iRT; reports board membership on Break Through Cancer; reports being an advisor to ACS BrightEdge; and is a founder and stockholder in Nanovista. JK reports participation on a data safety monitoring board and advisory board from Novartis (personal fees) and reports lecture honoraria from Monrol. JSL reports research support from Clarity Pharmaceuticals and Avid Radiopharmaceuticals; has acted as an adviser of Alpha-9 Theranostics, Clarity Pharmaceuticals, Earli, Evergreen Theragnostics, Suba Therapeutics, Inhibrx, Precirix, Solve, Goldman Sachs, TPG Capital, Curie Therapeutics, NextTech Invest, and Telix Pharmaceuticals; is secretary/treasurer of the Society of Nuclear Medicine and Molecular Imaging (SNMMI); holds equity in Curie Therapeutics, Summit Biomedical Imaging, Telix Pharmaceuticals, and Evergreen Theragnostics; and is supported by NIH R35 CA232130. YL reports funding to their institution for the European Society for Radiotherapy and Oncology (ESTRO) Chair on Health Economics in Radiation Oncology (HERO)–Value-Based Radiation Oncology, for a proton beam project from the Research Foundation Flanders (FWO)–Applied Biomedical Research with a Primary Finality, and for the ARCHERY trial; reports unpaid positions on advisory boards for the HALT trial and PROSECCA trial; is a member of the ESTRO Scientific Council and the Belgian Board of Oncology; is co-chair of the ESTRO-HERO project; and is principal investigator of the E2-Radiate trial, a joint project of ESTRO, and the European Organisation for Research and Treatment of Cancer (EORTC). JRP reports being an unpaid chair of the American Association of Physicists in Medicine (AAPM) International Council. AAR received consulting fees from Novartis; received honoraria for lectures from the European Society for Medical Oncology, Sociedade Brasileira de Mastologia, and Instituto Oncoclinicas; received financial support for attending meetings from ASTRO, Congresso Gramado, and Congresso Oncolinicas; reports an unpaid leadership position at the Sociedade Brasileira de Radioterapia; and has stock and stock options in Grupo Oncoclinicas. MMS reports research funding to their institution from Aktis, Point Biopharma, and Telix Pharmaceuticals; reports speaker honoraria from Novartis, Ion Beam Applications, and Johnson and Johnson; and holds positions in the Africa Health Research Institute and Adcock. VV holds positions as editor of the Journal of Clinical Oncology/Global Oncology and Translational Oncology and is a member of the board for City Cancer Challenge. RLW reports research funding to their institution from Siemens Healthineers, White Rabbit AI, Fusion, Perspective Therapeutics, Rayze, and Bayer; provides consulting services to Voximetry, Molecular Targeting Technologies (MTT), Perspective, Siemens, Abdera, and Seno; reports speaker payment from Hamad Health Qatar; reports travel support from Rayze and Hamad Health Qatar; has stock options in Voximetry and MTT; is a stockholder in Clarity Pharmaceuticals; participates on advisory boards for Perspective and Fusion; is a member of the SNMMI Mars Shot Board; and was a past president of SNMMI. JSY reports funding to their institution from the NIH, the IVY Foundation, and the Falk Research Medical Trust; reports honoraria from the University of Maryland and the Dana Farber/Harvard Cancer Center; and holds an unpaid position in the Clinical Advisory Council at the American Brain Tumor Association. AMS reports trial funding to their institution from EMD Serono, ITM, Telix Pharmaceuticals, AVID Radiopharmaceuticals, Fusion Pharmaceuticals, and Cyclotek; reports research funding to their institution from Medimmune, Antengene, Humanigen, and Telix Pharmaceuticals; is on advisory boards of Imagion and ImmunOs; reports unpaid board membership of the Australian and New Zealand Society of Nuclear Medicine and the World Federation of Nuclear Medicine and Biology; and is supported by a NHMRC Investigator grant (number 1177837). All other authors declare no competing interests., (Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)- Published
- 2024
- Full Text
- View/download PDF
28. Anemia of inflammation and iron metabolism in chronic diseases.
- Author
-
Conde Díez S, de Las Cuevas Allende R, and Conde García E
- Abstract
Anemia of Inflammation begins with the activation of the immune system and the subsequent release of cytokines that lead to an elevation of hepcidin, responsible for hypoferremia, and a suppression of erythropoiesis due to lack of iron. The anemia is usually mild/moderate, normocytic/normochromic and is the most prevalent, after iron deficiency anemia, and is the most common in patients with chronic diseases, in the elderly and in hospitalized patients. Anemia can influence the patient's quality of life and have a negative impact on survival. Treatment should be aimed at improving the underlying disease and correcting the anemia. Intravenous iron, erythropoietin and prolyl hydroxylase inhibitors are the current basis of treatment, but future therapy is directed against hepcidin, which is ultimately responsible for anemia., (Copyright © 2024 Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
29. Sex hormones and the total testosterone:estradiol ratio as predictors of severe acute respiratory syndrome coronavirus 2 infection in hospitalized men.
- Author
-
Ruiz-Ochoa D, Guerra-Ruiz AR, García-Unzueta MT, Muñoz-Cacho P, Rodriguez-Montalvan B, Amado-Diago CA, Lavín-Gómez BA, Cano-García ME, Pablo-Marcos D, and Vázquez LA
- Subjects
- Humans, Male, Middle Aged, Prospective Studies, Aged, SARS-CoV-2, Hospitalization, Adult, Predictive Value of Tests, COVID-19 blood, Estradiol blood, Testosterone blood, Biomarkers blood
- Abstract
Background: The predictive ability of the early determination of sex steroids and the total testosterone:estradiol ratio for the risk of severe coronavirus disease 2019 or the potential existence of a biological gradient in this relationship has not been evaluated., Objectives: To assess the relationship of sex steroid levels and the total testosterone:estradiol ratio with the risk of severe acute respiratory syndrome coronavirus 2 infection in men, defined as the need for intensive care unit admission or death, and the predictive ability of each biomarker., Materials and Methods: This was a prospective observational study. We included all consecutive adult men with severe acute respiratory syndrome coronavirus 2 infections in a single center admitted to a general hospital ward or to the intensive care unit. Sex steroids were evaluated at the centralized laboratory of our hospital., Results: We recruited 98 patients, 54 (55.1%) of whom developed severe coronavirus disease in 2019. Compared to patients with nonsevere coronavirus disease 2019, patients with severe coronavirus disease 2019 had significantly lower serum levels of total testosterone (111 ± 89 vs. 191 ± 143 ng/dL; p < 0.001), dehydroepiandrosterone (1.69 ± 1.26 vs. 2.96 ± 2.64 ng/mL; p < 0.001), and dehydroepiandrosterone sulfate (91.72 ± 76.20 vs. 134.28 ± 98.261 μg/dL; p = 0.009), significantly higher levels of estradiol (64.61 ± 59.35 vs. 33.78 ± 13.78 pg/mL; p = 0.001), and significantly lower total testosterone:estradiol ratio (0.28 ± 0.31 vs. 0.70 ± 0.75; p < 0.001). The lower the serum level of androgen and the lower the total testosterone:estradiol ratio values, the higher the likelihood of developing severe coronavirus disease 2019, with the linear trend in the adjusted analyses being statistically significant for all parameters except for androstenedione (p = 0.064). In the receiver operating characteristic analysis, better predictive performance was shown by the total testosterone:estradiol ratio, with an area under the curve of 0.77 (95% confidence interval 0.68-0.87; p < 0.001)., Discussion and Conclusion: Our results suggest that men with severe acute respiratory syndrome coronavirus 2 infection, decreased androgen levels and increased estradiol levels have a higher likelihood of developing an unfavorable outcome. The total testosterone:estradiol ratio showed the best predictive ability., (© 2024 The Authors. Andrology published by Wiley Periodicals LLC on behalf of American Society of Andrology and European Academy of Andrology.)
- Published
- 2024
- Full Text
- View/download PDF
30. A novel application of lemmatize and thematic analysis to understand protective measures perspectives of patients with chronic respiratory disease during the first outbreak of COVID-19 pandemic: a qualitative study.
- Author
-
Palacios-Ceña D, Peña-Otero D, Casanova-Macario C, Cuenca-Zaldivar JN, Garcia-Bravo C, Fernandez-de-Las-Peñas C, and Díaz-Pérez D
- Subjects
- Humans, Male, Aged, Female, Middle Aged, SARS-CoV-2, Pandemics, Interviews as Topic, Emotions, COVID-19 psychology, COVID-19 epidemiology, COVID-19 prevention & control, Pulmonary Disease, Chronic Obstructive psychology, Qualitative Research
- Abstract
Objective: To describe the perspectives of a group of COPD patients during the first outbreak of the COVID-19 pandemic and narrate the emotions and polarity (acceptance-rejection) regarding living with COPD during the pandemic., Design/methods: We used a novel application of lemmatization and thematic analysis of participants' narratives. A study was carried out with eight patients with moderate-severe-very severe COPD during the first outbreak of COVID-19 using purposive sampling. In-depth interviews and field notes from the researchers were used to collect data. A statistical content analysis (lemmatization) of the patients' narratives was performed. Additionally, inductive thematic analysis was used to identify emerging themes. This study was conducted following the guidelines of Consolidated Criteria/Standards for Reporting Qualitative Research. The study was conducted in accordance with the principles articulated in the WMA Declaration of Helsinki. Participants provided verbal informed consent prior to their inclusion as previously described., Results: The average age of our sample was 65 years, and 75% of the patients suffered from moderate COPD, 12.5% from severe COPD, and 12.5% from very severe COPD according to GOLD criteria. The lemmatized and sentiment analysis showed a predominance of positive emotions, and the polarity of the interviews indicated a very slight positive trend towards acceptance of the experience lived during the pandemic. Additionally, three main themes were identified: (1) Confinement and restriction measures, (2) COVID-19 and protective measures, and (3) Clinical care during the first outbreak of the pandemic., Conclusion: Patients experienced confinement with a feeling of security and protection. They strictly respect social distancing. They used masks, but these caused them to feel short of breath and fatigue, especially FFP2 masks. Half of the patients rejected the possibility of being vaccinated. Finally, they were very satisfied with the clinical care they received in the COPD unit of their hospital. Our results show that COPD patients have not experienced a negative impact of the COVID-19 pandemic., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Palacios-Ceña, Peña-Otero, Casanova-Macario, Cuenca-Zaldivar, Garcia-Bravo, Fernandez-de-las-Peñas and Díaz-Pérez.)
- Published
- 2024
- Full Text
- View/download PDF
31. ImmunoPET in high-grade neuroendocrine tumours.
- Author
-
Giammarile F, Delgado Bolton RC, Novruzov F, and Paez D
- Subjects
- Humans, Neoplasm Grading, Treatment Outcome, Neuroendocrine Tumors pathology, Neuroendocrine Tumors therapy
- Abstract
Competing Interests: We declare no competing interests.
- Published
- 2024
- Full Text
- View/download PDF
32. Partial-accelerated irradiation with stereotactic radiotherapy at a dose of 30 Gy in 5 fractions in early breast cancer.
- Author
-
Albendea Roch J, Anchuelo Latorre JT, Galdós Barroso MP, Navarrete Solano P, Rivero Pérez AL, Pinto Guevara F, García Lamela M, Olloqui Urroz J, Díaz de Tuesta M, Mazaira J, Muñoz P, and Prada Gómez PJ
- Subjects
- Humans, Female, Middle Aged, Aged, Adult, Carcinoma, Ductal, Breast radiotherapy, Carcinoma, Ductal, Breast pathology, Carcinoma, Ductal, Breast surgery, Carcinoma, Ductal, Breast mortality, Aged, 80 and over, Follow-Up Studies, Retrospective Studies, Mastectomy, Segmental, Breast Neoplasms radiotherapy, Breast Neoplasms surgery, Breast Neoplasms pathology, Breast Neoplasms mortality, Radiosurgery methods, Radiosurgery adverse effects, Feasibility Studies, Dose Fractionation, Radiation
- Abstract
Purpose: To evaluate feasibility of accelerated partial breast irradiation (APBI) using stereotactic radiotherapy (SBRT) Thirty Gy delivered in 5 fractions for patients with early breast cancer., Methods: Between January 1st, 2018, and December 31s, 2022, we conducted 117 treatments for patients with early-stage breast cancer. All patients underwent conservative surgery followed by APBI using stereotactic external beam radiotherapy. We analyzed local, regional, distant control, overall survival, toxicity, and cosmetic outcomes., Results: The average age was 62 years. 21.3% ductal and 78.7% invasive carcinomas. Regarding the PTV volume, the median was 198.8 cc (38-794 cc). Treatments were completed in all cases. The median follow-up period was of 21 months (1-62 months). Regarding acute toxicity, no Grade 3-4 toxicities were recorded. One patient experienced Grade 2 neuropathic pain. One patient developed subacute fibrosis and two patients developed telangiectasia as subacute and chronic toxicity. Cosmetic results were "good" or "very good" in 96.3% of cases. None of the patients relapsed at any level (local, regional, or distant) and overall survival during follow.up was 100%., Conclusion: APBI with SBRT 30 Gy in 5 fractions in early-stage breast cancer is a feasible technique, very-well tolerated and has excellent oncologic and cosmetic outcome during our follow-up period., (© 2024. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).)
- Published
- 2024
- Full Text
- View/download PDF
33. Medical Professionalism and Its Association with Dropout Intention in Peruvian Medical Students during the COVID-19 Pandemic.
- Author
-
Hancco-Monrroy DE, Caballero-Apaza LM, Abarca-Fernández D, Castagnetto JM, Condori-Cardoza FA, De-Lama Moran R, Carhuancho-Aguilar JR, Gutierrez S, Gonzales M, Berduzco N, Delgado Bolton RC, San-Martín M, and Vivanco L
- Abstract
Background: The COVID-19 pandemic introduced unprecedented challenges to medical education systems and medical students worldwide, making it necessary to adapt teaching to a remote methodology during the academic year 2020-2021. The aim of this study was to characterize the association between medical professionalism and dropout intention during the pandemic in Peruvian medical schools., Methods: A cross-sectional online-survey-based study was performed in four Peruvian medical schools (two public) during the academic year 2020-2021. Medical students, attending classes from home, answered three scales measuring clinical empathy, teamwork, and lifelong learning abilities (three elements of medical professionalism) and four scales measuring loneliness, anxiety, depression, and subjective wellbeing. In addition, 15 demographic, epidemiological, and academic variables (including dropout intention) were collected. Variables were assessed using multiple logistic regression analysis., Results: The study sample was composed of 1107 students (390 male). Eight variables were included in an explanatory model (Nagelkerke-R
2 = 0.35). Anxiety, depression, intention to work in the private sector, and teamwork abilities showed positive associations with dropout intention while learning abilities, subjective wellbeing, studying in a public medical school, and acquiring a better perception of medicine during the pandemic showed a negative association with dropout intention. No association was observed for empathy., Conclusions: Each element measured showed a different role, providing new clues on the influence that medical professionalism had on dropout intention during the pandemic. This information can be useful for medical educators to have a better understanding of the influence that professionalism plays in dropout intention.- Published
- 2024
- Full Text
- View/download PDF
34. Predictive values of indirect ultrasound signs for low risk of acute appendicitis in paediatric patients without visualisation of the appendix on ultrasound.
- Author
-
Pernía J, Cancho T, Segovia I, de Ponga P, Granda E, and Velasco R
- Subjects
- Humans, Child, Male, Female, Retrospective Studies, Adolescent, Child, Preschool, Emergency Service, Hospital, Spain, Appendectomy, Appendix diagnostic imaging, Appendicitis diagnostic imaging, Ultrasonography methods, Predictive Value of Tests
- Abstract
Background and Objectives: The ability to rule appendicitis in or out using ultrasound is limited by studies where the appendix is not visualised. We determined whether the absence of indirect ultrasound signs can rule out appendicitis in children undergoing a radiology-performed ultrasound in which the appendix is not visualised METHODS: This was a single-centre retrospective observational study of patients aged 3-13 with a clinical suspicion of acute appendicitis evaluated in a Paediatric Emergency Department in Spain from 1 January 2013 to 31 December 2019. For those patients who had formal ultrasound, direct and indirect findings of ultrasound were abstracted from the ultrasound report. The surgical pathology report was established as the gold standard in patients who underwent an appendectomy. In those who did not, appendicitis was considered not to be present if there was no evidence in their charts that they had undergone an appendectomy or conservative therapy for appendicitis during the episode. The main outcome variable was the diagnosis of acute appendicitis. For patients undergoing ultrasound, the independent association of each indirect ultrasound sign with the diagnosis of appendicitis in patients without a visualised appendix was analysed using logistic regression., Results: We included 1756 encounters from 1609 different episodes. Median age at the first visit of each episode was 10.1 years (IQR, 7.7-11.9) and 921 (57.2%) patients were men. There were 730 (41.6%) encounters with an Alvarado score ≤3, 695 (39.6%) with a score 4-6 and 331 (18.9%) with a score ≥7. Appendicitis was diagnosed in 293 (17.8%) episodes. Ultrasonography was performed in 1115 (61.6%) encounters, with a visualised appendix in 592 (53.1%).The ultrasound findings independently associated with appendicitis in patients without a visualised appendix were the presence of free intra-abdominal fluid in a small quantity (OR:5.0 (95% CI 1.7 to 14.6)) or in an abundant quantity (OR:30.9 (95% CI 3.8 to 252.7)) and inflammation of the peri-appendiceal fat (OR:7.2 (95% CI 1.4 to 38.0)). The absence of free fluid and inflammation of the peri-appendiceal fat ruled out acute appendicitis in patients with an Alvarado score <7 with a sensitivity of 84.6% (95% CI 57.8 to 95.7) and a negative predictive value of 99.4% (95% CI 97.8 to 99.8)., Conclusions: Patients with an Alvarado score <7 and without a visualised appendix on ultrasound but who lack free fluid and inflammation of the peri-appendiceal fat are at very low risk of acute appendicitis., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
35. Do we consider etanol consumption?
- Author
-
Velasco Montes J, González Díez S, and Rivas Cilleros E
- Published
- 2024
- Full Text
- View/download PDF
36. Challenges in the use of intravenous albumin in critically ill patients: Reflections and future perspectives.
- Author
-
González-Castro A, Ferrero-Franco R, and Blanco Huelga C
- Subjects
- Critical Care, Administration, Intravenous, Critical Illness therapy
- Published
- 2024
- Full Text
- View/download PDF
37. A rare resuscitation in a rare disease.
- Author
-
Corro Madrazo P
- Subjects
- Humans, Resuscitation methods, Male, Female, Rare Diseases therapy
- Published
- 2024
- Full Text
- View/download PDF
38. Emergencies in patients with disabilities.
- Author
-
Pastor AJ
- Subjects
- Humans, Disabled Persons, Emergencies
- Published
- 2024
- Full Text
- View/download PDF
39. Fibroblast Activation Protein Inhibitor (FAPI) PET Imaging in Sarcomas: A New Frontier in Nuclear Medicine.
- Author
-
Giammarile F, Knoll P, Paez D, Estrada Lobato E, Calapaquí Terán AK, and Delgado Bolton RC
- Subjects
- Humans, Gelatinases metabolism, Gelatinases antagonists & inhibitors, Animals, Endopeptidases, Serine Endopeptidases metabolism, Positron-Emission Tomography methods, Sarcoma diagnostic imaging, Nuclear Medicine methods, Membrane Proteins metabolism, Membrane Proteins antagonists & inhibitors
- Abstract
The field of nuclear medicine has witnessed significant advancements in recent years, particularly in the area of PET imaging. One such development is the use of Fibroblast Activation Protein Inhibitors (FAPI) as a novel radiotracer. FAPI PET imaging has shown promising results in various malignancies, including sarcomas, which are a diverse group of cancers originating from mesenchymal cells. This paper aims to explore the potential of FAPI PET imaging in the diagnosis, staging, and treatment monitoring of sarcomas. Several studies have demonstrated the potential of FAPI PET in sarcomas. Furthermore, FAPI PET imaging has shown potential in assessing treatment response, with changes in FAPI uptake correlating with treatment outcomes. However, there are challenges to be addressed. The heterogeneity of sarcomas, both inter- and intra-tumoral, may affect the uniformity of Fibroblast Activation Protein (FAP) expression and thus the effectiveness of FAPI PET imaging. Additionally, the optimal timing and dosage of FAPI for PET imaging in sarcomas need further investigation. In conclusion, the introduction of FAPI PET imaging represents a significant advancement in the field of nuclear medicine and oncology. The ability to target FAP, a protein overexpressed in the majority of sarcomas, offers new possibilities for the diagnosis and treatment of these complex and diverse tumors. Its potential applications in diagnosis, staging, and theranostics are vast, and on-going research continues to explore and address its limitations. As we continue to deepen our understanding of this novel imaging technique, it is hoped that FAPI PET imaging will play an increasingly important role in the fight against cancer. However, as with any new technology, further research is needed to fully understand the potential and limitations of FAPI PET imaging in the clinical setting., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
40. Guardians of precision: advancing radiation protection, safety, and quality systems in nuclear medicine.
- Author
-
Giammarile F, Knoll P, Kunikowska J, Paez D, Estrada Lobato E, Mikhail-Lette M, Wahl R, Holmberg O, Abdel-Wahab M, Scott AM, and Delgado Bolton RC
- Subjects
- Humans, Quality Control, Safety, Nuclear Medicine standards, Radiation Protection standards
- Abstract
Background: In the rapidly evolving field of nuclear medicine, the paramount importance of radiation protection, safety, and quality systems cannot be overstated. This document provides a comprehensive analysis of the intricate regulatory frameworks and guidelines, meticulously crafted and updated by national and international regulatory bodies to ensure the utmost safety and efficiency in the practice of nuclear medicine., Methods: We explore the dynamic nature of these regulations, emphasizing their adaptability in accommodating technological advancements and the integration of nuclear medicine with other medical and scientific disciplines., Results: Audits, both internal and external, are spotlighted for their pivotal role in assessing and ensuring compliance with established standards, promoting a culture of continuous improvement and excellence. We delve into the significant contributions of entities like the International Atomic Energy Agency (IAEA) and relevant professional societies in offering universally applicable guidelines that amalgamate the latest in scientific research, ethical considerations, and practical applicability., Conclusions: The document underscores the essence of international collaborations in pooling expertise, resources, and insights, fostering a global community of practice where knowledge and innovations are shared. Readers will gain an in-depth understanding of the practical applications, challenges, and opportunities presented by these regulatory frameworks and audit processes. The ultimate goal is to inspire and inform ongoing efforts to enhance safety, quality, and effectiveness in nuclear medicine globally., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
41. Impact of treatment adherence and inhalation technique on asthma outcomes of pediatric patients: a longitudinal study.
- Author
-
Lizano-Barrantes C, Garin O, Mayoral K, Dima AL, Pont A, Caballero-Rabasco MA, Praena-Crespo M, Valdesoiro-Navarrete L, Guerra MT, Bercedo-Sanz A, and Ferrer M
- Abstract
Introduction: We aimed to evaluate the longitudinal relationships, both at between- and within-person levels, that adherence to inhaled corticosteroid-based maintenance treatment and inhalation technique present with symptom control, exacerbations, and health-related quality of life (HRQoL) in children and adolescents with asthma. Methods: Participants (6-14 years old) from the ARCA (Asthma Research in Children and Adolescents) cohort-a prospective, multicenter, observational study (NCT04480242)-were followed for a period from 6 months to 5 years via computer-assisted telephone interviews and a smartphone application. The Medication Intake Survey-Asthma (MIS-A) was administered to assess the implementation stage of adherence, and the Inhalation Technique Questionnaire (InTeQ) was used to assess the five key steps when using an inhaler. Symptom control was measured with the Asthma Control Questionnaire (ACQ), and HRQL was measured with the EQ-5D and the Patient-Reported Outcomes Measurement Information System-Pediatric Asthma Impact Scale (PROMIS-PAIS). Multilevel longitudinal mixed models were constructed separately with symptom control, exacerbation occurrence, EQ-5D, and PROMIS-PAIS as the dependent variables. Results: Of the 360 participants enrolled, 303 (1,203 interviews) were included in the symptom control and exacerbation analyses, 265 (732) in the EQ-5D, and 215 (617) in the PROMIS-PAIS. Around 60% of participants were male subjects, and most of them underwent maintenance treatment with inhaled corticosteroids plus long-acting β-agonists in a fixed dose (73.3%). Within-person variability was 83.6% for asthma control, 98.6% for exacerbations, 36.4% for EQ-5D, and 49.1% for PROMIS-PAIS. At the within-person level, patients with higher adherence had better symptom control ( p = 0.002) and HRQoL over time ( p = 0.016). Patients with a better inhalation technique reported worse HRQoL simultaneously ( p = 0.012), but they showed better HRQoL in future assessments ( p = 0.012). The frequency of reliever use was associated with symptom control ( p < 0.001), exacerbation occurrence ( p < 0.001), and HRQoL ( p = 0.042); and boys were more likely to present better symptom control and HRQoL than girls. Conclusion: Our results confirm longitudinal associations at the within-person level of the two indicators of quality use of inhalers: for adherence to maintenance treatment with symptom control and HRQoL, and for the inhalation technique with HRQoL. Although treatment adherence was shown to be excellent, a third of the participants reported a suboptimal inhalation technique, highlighting the need for actions for improving asthma management of the pediatric population., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Lizano-Barrantes, Garin, Mayoral, Dima, Pont, Caballero-Rabasco, Praena-Crespo, Valdesoiro-Navarrete, Guerra, Bercedo-Sanz and Ferrer.)
- Published
- 2024
- Full Text
- View/download PDF
42. Expanding the evidence: A brief updated analysis of short-term mortality in conservative oxygen therapy versus liberal oxygen therapy in intensive care unit patients.
- Author
-
González-Castro A, Peñasco Y, Silva-Garcia C, Huertas Martin C, Gonzalez C, and Ferrero-Franco R
- Subjects
- Humans, Intensive Care Units, Oxygen therapeutic use, Oxygen Inhalation Therapy
- Published
- 2024
- Full Text
- View/download PDF
43. [A young male bike rider with intermittent Wolff-Parkinson-White syndrome].
- Author
-
Labrador-Descalzo S, Valle-Coca M, and Ruiz-Sainz F
- Subjects
- Humans, Male, Bicycling, Wolff-Parkinson-White Syndrome complications, Wolff-Parkinson-White Syndrome diagnosis
- Published
- 2024
- Full Text
- View/download PDF
44. Do we actively and early mobilize patients admitted to an intensive care unit during mechanical ventilation?
- Author
-
González-Castro A, Ferrero-Franco R, and Blanco-Uelga C
- Subjects
- Humans, Hospitalization, Respiration, Artificial, Intensive Care Units
- Published
- 2024
- Full Text
- View/download PDF
45. Clinical Application of ImmunoPET Targeting Checkpoint Inhibitors.
- Author
-
Abenavoli EM, Linguanti F, Calabretta R, Delgado Bolton RC, Berti V, and Lopci E
- Abstract
In the last decade, monoclonal antibodies (mAbs) targeting CTLA-4, PD-1, or PD-L1 have been developed and immune checkpoint inhibitors (ICIs) have become the main approach in cancer immunotherapy. However, not all patients benefit from ICI therapy and some are at risk of developing treatment-induced side-effects. These aspects, in parallel with the imaging challenges related to response assessments during immunotherapy, have driven scientific research to the discovery of new predictive biomarkers to individualize patients who could benefit from ICIs. In this context, molecular imaging using PET (positron emission tomography), which allows for whole-body tumor visualization, may be a promising non-invasive method for the determination of patients' sensitivity to antibody drugs. Several PET tracers, diverse from 2-[
18 F]FDG (or 2-Deoxy-2-[18 F]fluoroglucose), have been developed to image immune checkpoints (ICs) or key elements of the immune system, although most of them are still in preclinical phases. Herein, we present the current state of the ImmunoPET-targeting of IC proteins with mAbs and antibody fragments, with a main focus on the latest developments in clinical molecular imaging studies of solid tumors. Moreover, given the relevance of the immune system and of tumor-infiltrating lymphocytes in particular in the prediction of the benefit of ICIs, we dedicate a portion of this review to ImmunoPET-targeting T cells.- Published
- 2023
- Full Text
- View/download PDF
46. Montelukast in paediatric asthma and allergic rhinitis: a systematic review and meta-analysis.
- Author
-
Mayoral K, Lizano-Barrantes C, Zamora V, Pont A, Miret C, Barrufet C, Caballero-Rabasco MA, Praena-Crespo M, Bercedo A, Valdesoiro-Navarrete L, Guerra MT, Pardo Y, Martínez Zapata MJ, Garin O, and Ferrer M
- Subjects
- Adolescent, Humans, Child, Quality of Life, Adrenal Cortex Hormones therapeutic use, Asthma diagnosis, Asthma drug therapy, Rhinitis, Allergic diagnosis, Rhinitis, Allergic drug therapy
- Abstract
Background: We aim to assess the impact of montelukast on paediatric patients with asthma/allergic rhinitis, measured using patient-reported outcome measures, compared with other treatments or placebo., Methods: Protocol registration CRD42020216098 (www.crd.york.ac.uk/PROSPERO). MEDLINE and Embase databases were used to conduct the search. Two authors independently selected studies and extracted data, and a third reviewer resolved discrepancies. Meta-analyses were constructed to estimate the standardised mean difference (SMD) using a random-effects model., Results: Out of 3937 articles identified, 49 studies met the inclusion criteria, mostly randomised clinical trials (sample sizes: 21-689 patients). The SMD of change pooled estimators for the global, mental and physical domains of health-related quality of life were not statistically significant. For daytime and night-time symptoms scores, the SMD (95% CI) was in favour of inhaled corticosteroids (-0.12, -0.20- -0.05 and -0.23, -0.41- -0.06, respectively). The pooled estimator for global asthma symptoms was better for montelukast when compared with placebo (0.90, 0.44-1.36)., Conclusions: The synthesis of the available evidence suggests that, in children and adolescents, montelukast was effective in controlling asthma symptoms when compared with placebo, but inhaled corticosteroids were superior in controlling symptoms, especially at night-time. These findings of our systematic review concur with current guidelines for asthma treatment., Competing Interests: Conflict of interest: All authors have nothing to disclose., (Copyright ©The authors 2023.)
- Published
- 2023
- Full Text
- View/download PDF
47. Clinical simulation: A useful and underutilized training tool for the present and the future of learning in psychiatry.
- Author
-
Del Barrio AG, Vázquez-Bourgon J, Pellón JE, Maestre JM, and Gómez-Revuelta M
- Subjects
- Learning, Psychiatry education
- Published
- 2023
- Full Text
- View/download PDF
48. Prevalence and time trends of symptoms of allergic rhinitis and rhinoconjunctivitis in Spanish children: Global Asthma Network (GAN) study.
- Author
-
Bercedo-Sanz A, Martínez-Torres A, Varela AL, Belinchón FJP, Aguinaga-Ontoso I, Díaz CG, García-Marcos L, and Spain GG
- Subjects
- Adolescent, Child, Humans, Prevalence, Cross-Sectional Studies, Rhinitis epidemiology, Rhinitis, Allergic epidemiology, Asthma epidemiology, Conjunctivitis epidemiology
- Abstract
Introduction: The time trends of the prevalence of rhinitis, rhinoconjunctivitis and nasal allergy previously described in the ISAAC (International Study of Asthma and Allergies in Childhood) in 2002 are unknown; or if the geographical or age differences in Spain persist., Objective: To describe the prevalence of rhinitis, rhinoconjunctivitis and nasal allergy in different Spanish geographical areas and compare them with those of the ISAAC., Methods: Cross-sectional study of the prevalence of rhinitis, rhinoconjunctivitis and nasal allergy, carried out in 2016-2019 on 19943 adolescents aged 13-14 years and 17215 schoolchildren aged 6-7 years from six Spanish areas (Cartagena, Bilbao, Cantabria, La Coruña, Pamplona, and Salamanca), through a questionnaire based on the Global Asthma Network (GAN) protocol., Results: The prevalences of recent rhinitis and rhinoconjunctivitis (last 12 months), and nasal allergy/hay fever were 35.1%, 17.6%, and 14.6% in the adolescents and 20%, 8.5%, and 8.9% in the schoolchildren, respectively, with rhinoconjunctivitis in adolescents varying from 20.9% in Bilbao to 13.4% in Cartagena; and in schoolchildren, from 9.8% in La Coruña to 6.4% in Pamplona. These prevalences of rhinoconjunctivitis and nasal allergy in adolescents were higher than those described in the ISAAC (16.3% and 13%) and similar in schoolchildren to the ISAAC (9% and 9.4%)., Conclusions: There has been a stabilisation of rhinitis, rhinoconjunctivitis and nasal allergy in schoolchildren that slows the previous upward trend of ISAAC; and a slight non-significant increase in rhinoconjunctivitis and nasal allergy in adolescents. The variability found in adolescents would require local research to be better understood.
- Published
- 2023
- Full Text
- View/download PDF
49. Preventive interventions for children and adolescents of parents with mental illness: A systematic review.
- Author
-
Puchol-Martínez I, Vallina Férnandez Ó, and Santed-Germán MA
- Subjects
- Child, Adolescent, Humans, Parents psychology, Adaptation, Psychological, Mental Disorders prevention & control, Psychotic Disorders
- Abstract
Background: Children of parents with mental disorders have a relatively high risk of developing a mental illness or behavioural disorder., Objective: The aim of this systematic review was to evaluate the efficacy of preventive psychotherapeutic interventions in children of parents with mental illness. In particular, the development of mental illness and/or psychological symptomatology in this population was assessed., Method: This qualitative systematic review looked at interventions targeting children aged 4-18 years without a diagnosed mental disorder, alone or with their families, with a parent with a diagnosed mental disorder. The protocol was pre-registered in Open Science Framework. A total of 1255 references were retrieved from MEDLINE, PsychArticles, PsycINFO, Springer Link, Science Direct, Scopus and WOS databases, and 12 references from grey literature. This search was replicated by an external reviewer., Results: Fifteen studies involving 1941 children and 1328 parents were included. Interventions were based on cognitive-behavioural and/or psychoeducational components, including six randomized controlled trials. Internalizing symptomatology was assessed in 80% of the studies, externalizing and prosocial behaviour in 47%, and coping style in 33%. Only two studies measured the future risk of developing a mental disorder (ORs of 2.37 and 6.6). There was variability in the format of the intervention (group; family) as well as in the type of intervention and its duration (from one session to 12 sessions)., Conclusions: Interventions for children of parents with mental disorder were clinically and statistically significant, especially in preventing internalizing symptomatology at one-year follow-up, with effect sizes ranging from d = -0.28 to 0.57 (95% CI)., (© 2023 The Authors. Clinical Psychology & Psychotherapy published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
50. Prevalence of Incidental Findings Suspicious for Transthyretin Cardiac Amyloidosis among Patients Undergoing Bone Scintigraphy: A Systematic Review and a Meta-Analysis.
- Author
-
Treglia G, Martinello C, Dondi F, Albano D, Bertagna F, Rizzo A, Delgado Bolton RC, Tersalvi G, Muoio B, Riegger M, and Cecchin D
- Abstract
Background: The myocardial uptake of bone-seeking tracers suspicious for transthyretin cardiac amyloidosis (ATTR-CA) can be incidentally detected in patients undergoing bone scintigraphy for noncardiac reasons. We conducted a systematic review and meta-analysis to assess the prevalence of these scintigraphic findings., Methods: A comprehensive literature search was performed using two bibliographic databases (PubMed/MEDLINE and Cochrane Library), searching for articles related to the review question. Eligible articles were selected, and relevant data were extracted by two authors. The pooled prevalence of incidental findings suspicious for ATTR-CA among patients undergoing bone scintigraphy was calculated on a per-patient-based analysis using a random-effects model. The pooled measure was provided with 95% confidence interval (95% CI) values., Results: Among 219 records, 11 articles were selected for the systematic review and 10 for the meta-analysis. The pooled prevalence of incidental findings suspicious for ATTR-CA was 1.1% (95% CI: 0.7-1.4%) with heterogeneity due to the characteristics of the included studies, patients, and index tests. These findings are more prevalent in older men., Conclusions: The prevalence of incidental findings of ATTR-CA among patients undergoing bone scintigraphy is low but not negligible. Nuclear medicine physicians should suggest, in the scintigraphic report, further clinical investigations when these findings are detected. Prospective studies are warranted.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.